Program
amezosvatein
A development code. Also written as “CRV 101”.
Its studies are mostly in Herpes Zoster, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 10 open or running | phase 1since Jan 24, 2019 | Jan 24, 2019 | none ahead |
- Named in Eli Lilly’s own pipeline as
Amezosvatein
, phase 2, as of Oct 29, 2026 (source).
Also a collaborator on its studies: GC Biopharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2019First study: phase 1 study in Herpes ZosterFirst studyNCT03820414 · 90 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03820414Herpes Zoster · United States | 1 | Completed | Apr 4, 2020 | 90 |
How it is read
Names in the registry
- “CRV 101”, 1 entry
Codes read as this program: CRV101.
Conditions, from the studies’ own filings
- Herpes Zoster, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.